The most useful way to read a hospital operator's earnings is not as a profit-and-loss statement but as a capital allocation argument. Every revenue line and every margin compression tells you something about where management has chosen to deploy resources, what it expects from those resources in return, and whether the market has priced that bet correctly. Applied to Mouwasat Medical Services, Saudi Arabia's Dammam-based hospital group trading on Tadawul under ticker 4002, the picture that emerges from the most recent financial cycle is one of deliberate, disciplined expansion colliding with the unavoidable friction costs that any serious growth strategy produces. Understanding that collision is the essential task for anyone tracking Vision 2030 healthcare privatization stocks.

Start with the full-year 2025 numbers, because they establish the baseline from which everything else follows.

Mouwasat's revenue reached SAR 3.22 billion in 2025, an increase of 11.92% compared to the prior year, while earnings rose to SAR 822 million, a gain of 27.30%.

That earnings growth rate running materially ahead of revenue growth is the signature of operating leverage working in the company's favor, a sign that the existing hospital network was absorbing incremental patients without proportional cost increases.

Mouwasat has built a five-year dividend growth rate of 14.87%, a figure that reflects not just profitability but a management team confident enough in recurring cash generation to return capital consistently. The Mouwasat Medical earnings dividend story, in other words, is not a one-year event. It is a compounding track record.

The dividend mechanics confirm that confidence.

Shareholders approved a cash dividend of SAR 1 per share, representing 10% of capital, for the first half of 2025.

Then, at the May 2026 general assembly, the meeting approved a further SAR 225 million in cash dividends, or SAR 1.125 per share representing 11.25% of nominal value, for the second half of fiscal year 2025, with disbursement beginning May 14, 2026.

The combined full-year payout of SAR 2.125 per share reflects a payout ratio that remains disciplined.

Mouwasat's dividend is supported by earnings and cash flows, with payout ratios of approximately 51.7% and 60% respectively.

That headroom matters because the company is simultaneously funding a capital-intensive expansion program, and a payout ratio that leaves nearly half of earnings inside the business is precisely the structure that makes dividend sustainability credible through a construction cycle.

The expansion program is where the investment thesis gets genuinely complicated.

The Yanbu hospital project was approved in December 2018, with a SAR 295 million contracting deal signed in June 2022, and total construction and operational costs are estimated at SAR 500 million for a 40,000-square-meter facility comprising 200 beds and 60 clinics.

The opening of Mouwasat Hospital in Yanbu Industrial City forms part of the company's strategy to enhance its presence in the Kingdom's major cities.

That geographic logic is straightforward.

Mouwasat is the market leader in the Eastern Province with around 31% share of private beds, but a company whose dominance is geographically concentrated carries a structural risk that national competitors do not. Moving into Yanbu and, subsequently, Jeddah is not simply a growth story. It is a diversification imperative.

The Q1 2026 results show exactly what that imperative costs in the short run.

Revenues rose 9.1% year-on-year to SAR 833.8 million in Q1 2026, driven by higher inpatient occupancy rates, improved contractual terms with clients, and the commencement of operations at Mouwasat Hospital in Yanbu Industrial City as of February 1.

💡 Insight

Mouwasat's Jeddah hospital will face competition from HMG, which has a much stronger footprint in Riyadh, and from Fakeeh, which is similarly strong in Jeddah..

But the revenue contribution from Yanbu was accompanied by the margin drag that any new hospital produces before it reaches operational scale.

The company highlighted a flexible operating model that helped absorb pressure on profit margins resulting from its expansion strategy, particularly the ramp-up of the new Yanbu facility.

Net profit rose to SAR 201 million in Q1 2026, compared to SAR 197.1 million in the same period of 2025, a modest 2% gain that understates the underlying momentum of the mature hospital network.

The stock currently trades at a 2026 estimated price-to-earnings of 17.2 times against the sector's multiple of approximately 21 times, implying a discount of roughly 18%.

That discount is the market's way of pricing the ramp-up risk, and it is a reasonable thing to price. The question is whether it is being priced correctly.

Management's forward guidance suggests the Yanbu drag is temporary and well-understood.

Mouwasat's managing director indicated the company expects continued growth of revenues and net income during Q2 2026, with a higher growth rate than Q1.

This outlook is supported by increased operational efficiency and the rising revenue contribution of the new Yanbu hospital, in addition to stable performance across the company's other hospitals.

Management expects the Yanbu hospital's financial performance to accelerate gradually over the medium term as occupancy rates increase and operational efficiency improves, with the break-even point expected to be reached faster than in previous projects given operational experience and high regional demand.

The broader sectoral context matters here. The Tadawul healthcare IPO pipeline that has developed over the past two years reflects investor appetite for precisely the kind of privatization story that Mouwasat embodies at a more mature stage.

Healthcare generated approximately $508 million through listings in 2025, including SMC Hospitals on Tadawul's main market.

Healthcare remains central to the goals of Saudi Vision 2030, with the Kingdom seeking to expand healthcare access and develop the private medical sector, and listings like SMC support these ambitions by broadening public investment opportunities.

New listings attract capital and attention to the sector, but they also raise the competitive bar.

Mouwasat's Jeddah hospital will face competition from HMG, which has a much stronger footprint in Riyadh, and from Fakeeh, which is similarly strong in Jeddah.

The takeaway for investors tracking Saudi healthcare is this: Mouwasat Medical earnings and dividend data tell a story of a company that has earned the right to expand aggressively, having built a decade of compounding profitability and a payout track record that few regional peers can match. The Yanbu opening and the forthcoming Jeddah facility will compress margins in the near term. That compression is the price of geographic diversification, and the discount at which the stock currently trades relative to sector peers reflects that cost being recognized. The more consequential question is whether Mouwasat's operational discipline in the Eastern Province, where it built its dominant position, translates to the competitive markets of the west. The answer to that question, not the current dividend yield, is what will determine whether the sector discount closes or widens over the next two years.

For informational and research purposes only. This analysis is not a solicitation or offer. Consult a licensed financial advisor before making any investment decision.